EXPERIENCE OF APPLICATION AND SAFETY ASSESSMENT OF THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN UNDER-5 CHILDREN

Compulsory use of the 7-valent pneumococcal conjugate vaccine in the framework of national pediatric immunization schedules of the developed countries resulted in significant decrease in the prevalence of the pneumococcal infections induced by the vaccinal serotypes. However, a growth in prevalence of the pneumonia and acute otitis media caused by non-vaccinal strains has also been observed. This required introduction of a new 13-valent pneumococcal conjugate vaccine with a wider range of pneumococcal population coverage. The experience of application accumulated in various countries (2010 onwards) and results of the authors’ observations indicate high safety of the 13-valent pneumococcal conjugate vaccine for both healthy under-5 children and patients with various medical issues. The article presents results of the 13-valent pneumococcal conjugate vaccination tolerance assessment. The study involved 110 children from 2 months to 5 years of age. In most cases immunization concurred with other pediatric vaccines. The incidence of local reactions in vaccinated children did not exceed 33%, of generalized reactions – 11%. The authors observed a comparable incidence of side reactions in both virtually healthy children and children with various medical issues.

1. Estimated Hib and pneumococcal deaths for children under 5 years of age, 2008. World Health Organization. 2012; March. Available at: http://apps.who.int/immunization_monitoring/burden/Pneumo_hib_estimates/en/index.html

2. WHO Global Immunization Vision and Strategy, April 2005. Available at: www.who.int/vaccines/GIVS/english/Global_imm._data_EN.pdf

3. Bocchini J.A. Jr., Bradley J.S., Brady M.T., Bernstein H.H., Byington C.L., Fisher M.C., Glode M.P., Jackson M.A., Keyserling H.L., Kimberlin D.W., Orenstein W.A., Schutze G.E., Willoughby R.E. Jr. Recommendations for the Prevention of Streptococcus pneumonia Infections in Infants and Children: Use of 13-valent Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccaride Vaccine. Pediatrics. 2010 Jul; 126 (1): 186−90.

4. Paradiso P.R. Advances in pneumococcal disease prevention: 13-valent Pneumococcal Conjugate Vaccine for Infants and Children. Clin Infect Dis. 2011; 52 (10): 1241−1247.

5. Bettinger J.A., Scheifele D.W., Kellner J.D., Halperin S.A., Vaudry W., Law B., Tyrrell G., Morris R., Halperin S., Dеry P., Moore D., Lebel M., Le Saux N., Tran D., Embree J., Tan B., Jadavji T., Vaudry W., Sauvе L. The effect of routine vaccination on invasive pneumococcal infections in Canadian children, Immunization Monitoring Program, Active 2000–2007. Vaccine. 2010; 28: 2130−6.

6. Lehmann D., Willis J., Moore H.C., Moore H.C., Giele C., Murphy D., Keil A.D., Harrison C., Bayley K., Watson M., Richmond P. The changing epidemiology of invasive pneumococcal disease in aboriginal and non-aboriginal western Australians from 1997 through 2007 and emergence of nonvaccine serotypes. Clin Infect Dis. 2010; 50: 1477−86.

7. Rückinger S., van der Linden M., Reinert R.R., von Kries R., Burckhardt F., Siedler A. Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conjugate vaccine in Germany. Vaccine. 2009; 27: 4136−41.

8. Vestrheim D.F., Lovoll O., Aaberge I.S., Caugant D.A., Hоiby E.A., Bakke H., Bergsaker M.R. Effectiveness of a 2 + 1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway. Vaccine. 2008; 26: 3277−81.

9. Food and Drug Administration. Vaccines: approved products. Prevenar 13 (pneumococcal 13-valent conjugate vaccine). Available at: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm201667.htm. Accessed March 5, 2010.

10. Fedoseenko M.V., Namazova-Baranova L.S. International experience of pneumococcal conjugate vaccines: challenges, achievements and prospects. Voprosy sovremennoi pediatrii = Current Pediatrics. 2009; 8 (1): 136−9.

11. Licensure of a 13-Valent Pneumococcal Conjugate Vaccine (PCV13) and Recommendations for Use Among Children ― Advisory Committee on Immunization Practices (ACIP), 2010. Morbidity and Mortality Weekly Report (MMWR). Weekly. 2010 March 12; 59 (09): 258−61.

12. Baranov A.A., Namazova-Baranova L.S., Mayanskii N.A. et al. The role of Streptococcus pneumoniae in the structure of bacterial infections in children admitted to hospitals in Moscow in 2011-2012. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2013; 10 (5): 6−13.

13. Kozlov R.S. Pnevmokokkovaya infektsiya: sovremennye podkhody k profilaktike i terapii. Lektsii dlya praktikuyushchikh vrachei [Pneumococcal Disease: Current Approaches to Prevention and Therapy. Lectures for Practitioners]. Moscow, Zdorov'e cheloveka, 2005. P. 219−234.

14. Thompson A., Gurtman A., Patterson S. Safety of 13-valent pneumococcal conjugate vaccine in infants and children: meta-analysis of 13 clinical trials in 9 countries. Vaccine. 2013 Oct 25; 31 (45): 5289−95.

15. Ruiz-Aragón J. Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in infants: A meta-analysis. Vaccine. 2013; 31: 5349−58.

16. Bryant K.A., Block S.L., Baker S.A. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine. Pediatrics. 2010 May; 125 (5): 866−75.

17. Esposito S., Tansey S., Thompson A. Safety and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine Compared to Those of a 7-Valent Pneumococcal Conjugate Vaccine Given as a Three-Dose Series with Routine Vaccines in Healthy Infants and Toddlers. Clin Vaccine Immunol. 2010 Jun; 17 (6): 1017–26.

18. Vanderkoii O.G., Scheifele D.W., Girgenti D., Halperin S.A., Patterson S.D., Gruber W.C., Emini E.A., Scott D.A., Kellner J.D. Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccination in Canada. Pediatr Infect Dis J. 2012 Jan; 31 (1): 72−7.

19. Kieninger D.M., Kueper K., Steul K., Juergens C., Ahlers N., Baker S., Jansen K.U., Devlin C., Gruber W.C., Emini E.A., Scott D.A. Safety, tolerability and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccination in Germany. Vaccine. 2010 Jun; 7 (28): 25.

20. Togashi T., Yamaji M., Thompson A., Giardina P.C., Aizawa M., Patterson S., Gruber W.C., Scott D.A. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in health infants in Japan. Pediatr Infect Dis J. 2013 Sep; 32 (9): 984−9.

21. Gutierez Brito M., Thompson A., Girgenti D., Giardina P.C., Sarkozy D.A., Gruber W.C., Emini E.A., Scott D.A. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in Mexico. Rev Panam Salud Publica. 2013 Jun; 33 (6): 414−21.

22. Weckx L.Y., Thompson A., Berezin E.N., de Faria S.M., da Cunha C.A., Pride M., Patterson S., Gruber W.C., Emini E.A., Scott D.A. A phase 3, randomized, double-blind trial comparing the safety and immunogenicity of the 7-valent and 13-valent pneumococcal conjugate vaccines, given with routine pediatric vaccinations, in healthy infants in Brazil. Vaccine. 2012 Dec 14; 30 (52): 7566−72.

23. Tseng H.F., Sy L.S., Liu I.L., Qian L., Marcy S.M., Weintraub E., Yih K., Baxter R., Glanz J.M., Donahue J., Naleway A., Nordin J., Jacobsen S.J. Postlicenzure surveillance for pre-specified adverse events following the 13-vallent pneumococcal conjugate vaccine in children. Vaccine. 2013 May 24; 31 (22): 2578−83.

24. Il'ina S.V., Beletskaya O.A., Sabitov A.U., Chernaya N.L., Snegova N.F., Salkina O.A., Dzhumagaziev A.A., Bakhareva N.V., Brovkina A.A., Savvina N.V. The results of evaluation of the effectiveness and safety of conjugate pneumococcal vaccines in the Russian Federation. Epidemiologiya i infektsionnye bolezni, aktual'nye voprosy = Epidemiology and infectious diseases, topical issues. 2013; 6: 55−60.

25. Il'ina S.V., Lysanov Yu.I. Vaccination Pneumococcal conjugate vaccine in preterm infants and children with congenital heart disease in Irkutsk. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2013; 10 (3): 12−16.

26. Gaivoronskaya A.G., Namazova-Baranova L.S., Galitskaya M.G., Grechukha T.A., Tkachenko N.E., Ivardava M.I. Analysis of the efficacy and safety of vaccination against pneumococcal disease for children with various disabilities in health. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2012; 9 (2): 10−14.